CannaPharmaRX, Inc.
CPMD · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.07 | -0.00 | 0.01 | 0.00 |
| FCF Yield | 0.00% | -17.28% | -22.69% | -3.55% |
| EV / EBITDA | -16.42 | -27.75 | -391.82 | -12.85 |
| Quality | ||||
| ROIC | 26.87% | 17.69% | 17.85% | 26.46% |
| Gross Margin | 0.00% | -268.22% | -150.01% | -350.73% |
| Cash Conversion Ratio | – | 0.32 | 0.87 | 0.05 |
| Growth | ||||
| Revenue 3-Year CAGR | 308.87% | 279.25% | 256.39% | 220.32% |
| Free Cash Flow Growth | 100.00% | 25.76% | -234.30% | 66.74% |
| Safety | ||||
| Net Debt / EBITDA | -14.30 | -24.23 | -338.33 | -9.45 |
| Interest Coverage | 1.85 | -1.28 | -1.09 | -4.72 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.82 | 0.88 | 2.18 |
| Cash Conversion Cycle | 80.65 | -412.41 | -366.33 | -153.05 |